在接受Keytruda治疗2年的患者中,3-5级的TRAE发生率为15.4%。 原文出处:First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ...
The estimated three-year event-free survival rates were 84.5 percent in the Keytruda group and 76.8 percent in the chemotherapy-placebo group. Notably, the safety profile of the Keytruda regimen was consistent with the known profiles of each regimen, and researchers identified no new...
在接受Keytruda治疗2年的患者中,3-5级的TRAE发生率为15.4%。 原文出处:First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ...
First-line treatment withKeytruda(pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastaticnon-small cell lung cancer(NSCLC) and high levels ofPD-L1, compared with standard chemotherapy, according to five-year data ...
The approval is based on data from the Phase 3 KEYNOTE-859 trial, in which Keytruda plus chemotherapy reduced the risk of death by 22% (HR=0.78 [95% CI, 0.70‑0.87]; p<0.0001) compared to chemotherapy alone for these patients. Median overall survival (OS) was 12.9...
原文出处:KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer ...
for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit ...
KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. This indication ...
A greater number of patients receiving Keytruda had their bladder cancer tumors shrink (21%) compared to chemotherapy (11%). Bottom Line In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer ...
The requested medication will be used as first line therapy as a single agent or in combination with platinum and fluoropyrimidine-based chemotherapy for microsatellite instability-high or deficient mismatch repair tumors;or The requested medication will be used as single agent subsequent therapy with PD...